ArticleGEN biotechnology2025
Long-Term Suppression of RUNX2 During MSC-Based Cartilage Formation Increases Cartilage Matrix Accumulation.
Article in GEN biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to evaluate the long-term effects of an autonomous RUNX2-supressing gene circuit on cartilage matrix accumulation and compressive mechanics in the tissues produced by MSC-derived chondrocytes (MdChs). Human mesenchymal stem cells (MSCs) were differentiated into chondrocytes and genetically modified using a lentiviral short hairpin RNA (shRNA) targeting RUNX2 (shRUNX2). Two configurations, low and high levels of shRUNX2 expression, were implemented. The influence on RUNX2 suppression, matrix protein secretion, and compressive mechanics was evaluated. Both low and high shRUNX2 suppressed RUNX2 expression, showing significant improvement in cartilage matrix accumulation with increased collagen type II and aggrecan deposition. High shRUNX2 more effectively suppresses RUNX2 gene expression and enhances sulfated glycosaminoglycan and matrix accumulation compared with the control and low shRUNX2 group. This study demonstrates the long-term effect of autonomous RUNX2 suppression in enhancing cartilage matrix accumulation and mechanical properties, providing a promising approach for advancing cartilage tissue engineering and repair strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.